Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00003931
Status:
COMPLETED
Last Update Posted:
2016-07-04
First Post:
1999-11-01
Brief Title:
Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia
Sponsor:
Alliance for Clinical Trials in Oncology
Organization:
Alliance for Clinical Trials in Oncology
Study Overview
Official Title:
Assessment of the Partial Tandem Duplication of ALL1 MLL in Patients With Acute Myeloid Leukemia- A CALGB Leukemia Tissue Bank Project
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Diagnostic procedures such as genetic testing may improve the ability to detect acute myeloid leukemia and determine the extent of disease
PURPOSE Diagnostic study to try to detect changes in the genes of patients who have acute myeloid leukemia
PURPOSE Diagnostic study to try to detect changes in the genes of patients who have acute myeloid leukemia
Detailed Description:
OBJECTIVES
Determine the frequency of partial tandem duplication of ALL1 MLL in patients with acute myeloid leukemia AML
Determine the predictive value of partial tandem duplication of ALL1 to identify a subset of AML patients who have a short duration of complete remission
OUTLINE All samples are obtained from specimens collected on CALGB-9665 No additional blood or bone marrow samples are collected
Samples are examined by Southern blot analysis for gene rearrangement at 11q23 Samples showing evidence of ALL1 gene rearrangement are further analyzed by reverse transcription PCR amplification andor cytogenetic analysis to detect partial tandem duplication of ALL1
Determine the frequency of partial tandem duplication of ALL1 MLL in patients with acute myeloid leukemia AML
Determine the predictive value of partial tandem duplication of ALL1 to identify a subset of AML patients who have a short duration of complete remission
OUTLINE All samples are obtained from specimens collected on CALGB-9665 No additional blood or bone marrow samples are collected
Samples are examined by Southern blot analysis for gene rearrangement at 11q23 Samples showing evidence of ALL1 gene rearrangement are further analyzed by reverse transcription PCR amplification andor cytogenetic analysis to detect partial tandem duplication of ALL1
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U10CA031946 | NIH | None | None |
| CLB-9769 | None | None | None |
| CDR0000067123 | REGISTRY | NCI Physician Data Query | httpsreporternihgovquickSearchU10CA031946 |